Tetanus Clinical Trials Tetanus RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
Condition:   Tetanus Interventions:   Drug: TNM002;   Drug: Human tetanus immunoglobulin (HTIG) Sponsor:   Trinomab Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2022 Category: Research Source Type: clinical trials